<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02837081</url>
  </required_header>
  <id_info>
    <org_study_id>VGHKS15-CT12-05</org_study_id>
    <nct_id>NCT02837081</nct_id>
  </id_info>
  <brief_title>Preauthorization Versus Prospective Audit in Antimicrobial Stewardship Program</brief_title>
  <official_title>The Impact of Preauthorization Compared to Prospective Audit on Outcome Indicators as Core Strategies of Antimicrobial Stewardship Program</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kaohsiung Veterans General Hospital.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kaohsiung Veterans General Hospital.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Antimicrobial stewardship program (ASP) is recommended to improve appropriate antimicrobial
      use, reduce bacterial resistance, unnecessary drug costs and enhance patient health outcomes.
      Two core strategies of ASP recommended as effective in guidelines are formulary restriction
      with drug preauthorization and prospective audit with feedback. Investigators will evaluate
      the effectiveness of the 2 strategies using antimicrobial utilization and patient outcomes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background: Antimicrobial stewardship program (ASP) is recommended to improve appropriate
      antimicrobial use, reduce bacterial resistance, unnecessary drug costs and enhance patient
      health outcomes. Two core strategies of ASP recommended as effective in guidelines are
      formulary restriction with drug preauthorization and prospective audit with feedback.
      Preauthorization is the current strategy used in our hospital, while most other hospitals in
      Taiwan and worldwide uses prospective audit with feedback. Preauthorization requires
      intensive manpower to maintain timeliness of antimicrobial use. This study will evaluate a
      policy change in strategy used for antimicrobial stewardship. Investigators will evaluate the
      effectiveness of the 2 strategies using antimicrobial utilization and patient outcomes.

      Methods: During a stepwise change in the policy of the antimicrobial stewardship program in
      this hospital, the study will observe the differences between two standardized core
      strategies (preauthorization vs prospective audit) of ASP. Hospitalized patients aged 20 and
      above, requiring use of restricted antimicrobials will be recruited into the study. Signing
      of consent forms are waived since both strategies are already proven to be effective and are
      widely implemented in Taiwan and worldwide. Also, the evaluation of such policy changes will
      not impact on patient safety or patient rights. The conduction of the study will not require
      contacting patients and no clinical samples will be collected. All data required for analysis
      will be collected via a computerized patient care system. Patient data will be protected via
      de-linking. Patients will be excluded if admitted at or entered the intensive care unit
      within 48 hours of entry, and if infectious diseases consultation had been requested.
      Eligible patients will be randomized to either preauthorization, which is the current
      practice in the hospital; or prospective audit, that will be done at 48-72 hours after
      prescription, as is the current practice in other hospitals in Taiwan and worldwide. Managing
      physicians are not obligated to follow our advice and the investigators will not intervene in
      their management decisions. Primary outcomes include antimicrobial utilization, drug costs
      and patient outcomes such as length of stay and clinical improvement. The time spent on
      implementing these two strategies will be compared.

      The study hypothesis is that the preauthorization group will impact on a reduction in
      antimicrobial cost and utilization, especially in the first 72 hours, when compared to
      prospective audit. However, patient outcomes will likely be similar. Antimicrobial
      stewardship programs using preauthorization as a core strategy compared to prospective audit
      with feedback have similar patient outcomes, but may reduce antimicrobial utilization.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2015</start_date>
  <completion_date type="Anticipated">March 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Antimicrobial utilization using defined daily dose (DDD)</measure>
    <time_frame>4 weeks</time_frame>
    <description>Defined daily dose (DDD),</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Antimicrobial utilization using defined daily dose per 1000 patient days (DID)</measure>
    <time_frame>4 weeks</time_frame>
    <description>Defined daily dose per 1000 patient days</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Appropriateness of antimicrobial prescription by susceptibility of culture</measure>
    <time_frame>4 weeks</time_frame>
    <description>cultures shows susceptibility to antimicrobial prescribed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of acceptance to use antimicrobial agents recommended by infectious disease physicians</measure>
    <time_frame>4 weeks</time_frame>
    <description>choice of antimicrobial agents used matches recommendation by infectious diseases physician</description>
  </secondary_outcome>
  <other_outcome>
    <measure>30-day mortality</measure>
    <time_frame>30 days post randomization</time_frame>
    <description>mortality rate at 30-days post randomization</description>
  </other_outcome>
  <other_outcome>
    <measure>3-day defervescence rate</measure>
    <time_frame>3 day post randomization</time_frame>
    <description>Rate of defervescence on day 3 post randomization</description>
  </other_outcome>
  <other_outcome>
    <measure>Rate of hospital associated bloodstream infections</measure>
    <time_frame>12 months</time_frame>
    <description>overall rate of bloodstream infection within the hospital during the study period</description>
  </other_outcome>
  <other_outcome>
    <measure>Rates of multidrug resistant organisms within the hospital</measure>
    <time_frame>12 months</time_frame>
    <description>Rates of carbapenem-resistant Acinetobacter baumanii (CRAB), vancomycin resistant Enterococcus (VRE), Clostridium difficile</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1060</enrollment>
  <condition>Bacterial Infections</condition>
  <arm_group>
    <arm_group_label>Preauthorization group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Strategy 1 of antimicrobial stewardship: Prescriptions of antimicrobial agents are done real-time by infectious diseases physician consultant. Use restricted without real-time authorization.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prospective audit</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Strategy 2 of antimicrobial stewardship: Prescription of antimicrobial agents are audited 48-72 hours later by infectious diseases physician consultant. Use allowed without authorization for 72 hours.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Prospective audit strategy of antimicrobial stewardship</intervention_name>
    <description>applying prospective audit as a different strategy of antimicrobial stewardship</description>
    <arm_group_label>Prospective audit</arm_group_label>
    <other_name>prospective audit</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>preauthorization strategy of antimicrobial stewardship</intervention_name>
    <description>applying preauthorization as one strategy of antimicrobial stewardship</description>
    <arm_group_label>Preauthorization group</arm_group_label>
    <other_name>preauthorization</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  In-hospital patients, aged 20 and above, with request from managing physicians for use
             of restricted antimicrobials.

        Exclusion Criteria:

          -  Patients admitted to the intensive care unit at evaluation or within 48 hours of entry
             into the study.

          -  Patients with antimicrobial prescriptions prescribed during after-hours, including
             weekends and public holidays.

          -  Formal infectious disease consultations requested prior to randomization.

          -  Patients in the emergency department and outpatient department.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Susan Shin-Jung Lee, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kaohsiung Veterans General Hospital.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Susan Shin-Jung Lee, M.D., Ph.D.</last_name>
    <phone>+886-7-342-2121</phone>
    <phone_ext>2029</phone_ext>
    <email>ssjlee28@yahoo.com.tw</email>
  </overall_contact>
  <location>
    <facility>
      <name>Kaohsiung Veterans General Hospital</name>
      <address>
        <city>Kaohsiung</city>
        <zip>813</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan Shin-Jung Lee, M.D., M.Sc.</last_name>
      <phone>+886-968971300</phone>
      <email>ssjlee28@yahoo.com.tw</email>
    </contact>
    <contact_backup>
      <last_name>Kelly Yen-Yun Ni, R.N.</last_name>
      <phone>+886-73422121</phone>
      <phone_ext>2029</phone_ext>
      <email>ni0630b@yahoo.com.tw</email>
    </contact_backup>
    <investigator>
      <last_name>Susan Shin-Jung Lee, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yao-Shen Chen, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hung-Chin Tsai, M.D., Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jui-Kuang Chen, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Cheng-Len Sy, M.D., BSMT</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kuan-Sheng Wu, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yu-Ting Tseng, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pi-Han Hung, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <results_reference>
    <citation>Society for Healthcare Epidemiology of America; Infectious Diseases Society of America; Pediatric Infectious Diseases Society. Policy statement on antimicrobial stewardship by the Society for Healthcare Epidemiology of America (SHEA), the Infectious Diseases Society of America (IDSA), and the Pediatric Infectious Diseases Society (PIDS). Infect Control Hosp Epidemiol. 2012 Apr;33(4):322-7. doi: 10.1086/665010.</citation>
    <PMID>22418625</PMID>
  </results_reference>
  <results_reference>
    <citation>W.H.O. (2011) WHO Global Strategy for Containment of Antimicrobial Resistance.</citation>
  </results_reference>
  <results_reference>
    <citation>Tseng SH, Lee CM, Lin TY, Chang SC, Chuang YC, Yen MY, Hwang KP, Leu HS, Yen CC, Chang FY. Combating antimicrobial resistance: antimicrobial stewardship program in Taiwan. J Microbiol Immunol Infect. 2012 Apr;45(2):79-89. doi: 10.1016/j.jmii.2012.03.007. Epub 2012 Apr 5. Review. Erratum in: J Microbiol Immunol Infect. 2012 Aug;45(4):326-7.</citation>
    <PMID>22483434</PMID>
  </results_reference>
  <results_reference>
    <citation>Dellit TH, Owens RC, McGowan JE Jr, Gerding DN, Weinstein RA, Burke JP, Huskins WC, Paterson DL, Fishman NO, Carpenter CF, Brennan PJ, Billeter M, Hooton TM; Infectious Diseases Society of America; Society for Healthcare Epidemiology of America. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis. 2007 Jan 15;44(2):159-77. Epub 2006 Dec 13.</citation>
    <PMID>17173212</PMID>
  </results_reference>
  <results_reference>
    <citation>Chung GW, Wu JE, Yeo CL, Chan D, Hsu LY. Antimicrobial stewardship: a review of prospective audit and feedback systems and an objective evaluation of outcomes. Virulence. 2013 Feb 15;4(2):151-7. doi: 10.4161/viru.21626. Epub 2013 Jan 9. Review.</citation>
    <PMID>23302793</PMID>
  </results_reference>
  <results_reference>
    <citation>Lin YS, Lin IF, Yen YF, Lin PC, Shiu YC, Hu HY, Yang YP. Impact of an antimicrobial stewardship program with multidisciplinary cooperation in a community public teaching hospital in Taiwan. Am J Infect Control. 2013 Nov;41(11):1069-72. doi: 10.1016/j.ajic.2013.04.004. Epub 2013 Jul 17.</citation>
    <PMID>23870295</PMID>
  </results_reference>
  <results_reference>
    <citation>Teng CB, Ng TM, Tan MW, Tan SH, Tay M, Lim SF, Ling LM, Ang BS, Lye DC. Safety and effectiveness of improving carbapenem use via prospective review and feedback in a multidisciplinary antimicrobial stewardship programme. Ann Acad Med Singapore. 2015 Jan;44(1):19-25.</citation>
    <PMID>25703493</PMID>
  </results_reference>
  <results_reference>
    <citation>Reed EE, Stevenson KB, West JE, Bauer KA, Goff DA. Impact of formulary restriction with prior authorization by an antimicrobial stewardship program. Virulence. 2013 Feb 15;4(2):158-62. doi: 10.4161/viru.21657. Epub 2012 Nov 15. Review.</citation>
    <PMID>23154323</PMID>
  </results_reference>
  <results_reference>
    <citation>Mehta JM, Haynes K, Wileyto EP, Gerber JS, Timko DR, Morgan SC, Binkley S, Fishman NO, Lautenbach E, Zaoutis T; Centers for Disease Control and Prevention Epicenter Program. Comparison of prior authorization and prospective audit with feedback for antimicrobial stewardship. Infect Control Hosp Epidemiol. 2014 Sep;35(9):1092-9. doi: 10.1086/677624. Epub 2014 Jul 23.</citation>
    <PMID>25111916</PMID>
  </results_reference>
  <results_reference>
    <citation>Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373-83.</citation>
    <PMID>3558716</PMID>
  </results_reference>
  <results_reference>
    <citation>W.H.O. Defined Daily Dose (DDD). 2015 [cited 2015 May 24]; Available from: http://www.whocc.no/ddd/definition_and_general_considera/.</citation>
  </results_reference>
  <results_reference>
    <citation>van den Bosch CM, Geerlings SE, Natsch S, Prins JM, Hulscher ME. Quality indicators to measure appropriate antibiotic use in hospitalized adults. Clin Infect Dis. 2015 Jan 15;60(2):281-91. doi: 10.1093/cid/ciu747. Epub 2014 Sep 28.</citation>
    <PMID>25266285</PMID>
  </results_reference>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 1, 2015</study_first_submitted>
  <study_first_submitted_qc>July 14, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 19, 2016</study_first_posted>
  <last_update_submitted>July 14, 2016</last_update_submitted>
  <last_update_submitted_qc>July 14, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 19, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Kaohsiung Veterans General Hospital.</investigator_affiliation>
    <investigator_full_name>Susan Shin-Jung Lee</investigator_full_name>
    <investigator_title>Attending physician</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bacterial Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Infective Agents</mesh_term>
    <mesh_term>Anti-Bacterial Agents</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

